document.getElementById('index-articles-list').innerHTML = `

A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma

Rachel Dileo,Prerna Mewawalla,Kalaivani Babu et al.

Blood cancer journal. 2025 Mar 10;15(1):34. DOI:10.1038/s41408-025-01226-8

Different definitions in intention-to-treat analysis for chimeric antigen receptor T-cell therapy depend on research scope

Lisa Argnani,Beatrice Casadei,Pier Luigi Zinzani

Blood cancer journal. 2025 Mar 7;15(1):33. DOI:10.1038/s41408-025-01246-4

Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma

James A Davis,Jordan Snyder,Mikhaila Rice et al.

Blood cancer journal. 2025 Mar 4;15(1):32. DOI:10.1038/s41408-025-01222-y

Evolution of WHO diagnostic criteria in "Classical Myeloproliferative Neoplasms" compared with the International Consensus Classification

Jürgen Thiele,Hans Michael Kvasnicka,Umberto Gianelli et al.

Blood cancer journal. 2025 Mar 4;15(1):31. DOI:10.1038/s41408-025-01235-7

Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel

Vaishali Dulobdas,Amy A Kirkwood,Fabio Serpenti et al.

Blood cancer journal. 2025 Mar 4;15(1):30. DOI:10.1038/s41408-025-01225-9

`; document.getElementById('index-articles-more').href = `https://i.iikx.com/journal/2044-5385.html`; document.getElementById('index-articles-more').innerHTML='更多内容'; document.getElementById('index-articles-more').style="float:right;background:var(--primary-color);color:#fff;font-size:13px;border-radius:5px;padding:0px 10px;margin-right:5px;line-height:1.7"; document.getElementsByClassName('index-artcles')[0].style.display = 'block'; document.getElementById('showJournalIndexUrl').style.display = 'block'; document.querySelector('#showJournalIndexUrl a').href = `https://i.iikx.com/journal/2044-5385.html`;